Navigation Links
University of Glasgow Becomes a Member of GeneGo's MetaMiner Stem Cell Partnership Program
Date:1/27/2009

ST. JOSEPH, Mich., Jan. 27 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that Professor Nicol Keith of the University of Glasgow will join the MetaMiner Stem Cell Partnership Program. The goal of the program is to develop a series of blueprint pathway maps for Adult, Embryonic, Fetal, Fibroblasts, Hematopoietic, Mesenchymal, Multipotent, Neoplastic, Pluripotent and Totipotent stem cells.

"We feel that it is important to support such an initiative as there is a lot of stem cell information in the literature but no one has brought it all together in a set of comprehensive pathway maps," said Nicol Keith, Professor of Molecular Oncology. "This initiative will allow researchers to have more of a global perspective and allows newcomers to the field to get up to speed quickly."

"Professor Nicol Keith, of the University of Glasgow in Scotland is world renowned for his pioneering work in cellular immortality and we are pleased to have him on our team," said Julie Bryant, GeneGo's VP of Business Development. "We have a lot of experience at building pathway maps and we plan to have 10 types of stem cell pathway maps completed in 24 months."

About GeneGo, Inc.

GeneGo, Inc. develops systems biology technology such as compound based pathway analysis, cheminformatics & bioinformatics software for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 5.2(TM), assists pharmaceutical scientists in the areas of target selection and validation, data mining in biology, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 5.2(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore.

For more information, please visit the company's web site at www.genego.com.


'/>"/>
SOURCE GeneGo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers
2. University of Helsinki and ASM International renew research agreement on atomic layer deposition
3. Cell Biosciences Delivers Next Generation System to Stanford University
4. RainDance Technologies and Harvard University to Share in First Massachusetts Life Sciences Center Cooperative Research Grants
5. University of Minnesota Receives $40 Million for Type 1 Diabetes Research
6. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
7. Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market
8. Delcath Adds University of Pittsburgh Medical Center to Phase III Trial
9. University of Florida and Cyntellect Collaborate to Unlock Mysteries of Cancer Stem Cells
10. Full Sail University Welcomed Back to Campus Graduate and Acclaimed Horror Director, Darren Lynn Bousman
11. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- NetworkNewsWire Editorial Coverage  ... Cancer remains one of the ... care systems, in terms of costs and resources. However, as ... development of innovative and efficient therapies that demonstrate higher chances ... of cancer treatments, a growing number of patients receiving immuno-oncology ...
(Date:3/22/2017)... N.Y. , March 22, 2017 Regeneron Pharmaceuticals, ... the Regeneron Genetics Center (RGC), U.K. Biobank and GSK to ... the U.K. Biobank resource. The initiative will enable researchers to ... new medicines for a wide range of serious and life ... ...
(Date:3/22/2017)... 22, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... www.oramed.com ), a clinical-stage pharmaceutical company ... systems, announced today that Dr. Miriam Kidron ... presentation titled, "Oral Insulin for Diabetes Treatment: Bypassing ... Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:2/28/2017)... LOS ANGELES , Feb. 28, 2017   ... identity verification software globally, announces significant enhancements to new ... in May 2016. New products include mobile and desktop ... and DocX TM - a real time manual ... Acuant,s core idScan® technology provides the fastest and most ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
Breaking Biology News(10 mins):